Clinical Trials
Advancing the treatment of solid tumor cancers
Backed by robust preclinical studies, we are conducting clinical trials across a range of solid tumors to investigate our unique TmodTM CAR T cell therapy. Ongoing trials are actively recruiting participants.
BASECAMP-1 pre-screening study
BASECAMP-1 is a pre-screening study to identify patients for potential treatment in our clinical trials.
BASECAMP-1 is currently enrolling patients with non-small cell lung, colorectal, pancreatic and ovarian cancers, as well as mesothelioma.
Objective: Use next-generation sequencing to identify patients with solid tumors that have lost human leukocyte antigen (HLA), then perform leukapheresis to collect, process and store patient T cells for future Tmod CAR T cell therapy.
Study design: Non-interventional, observational study to evaluate patients with solid tumors at a high risk of relapse. Participants that meet all the criteria may be enrolled and leukapheresed. Participants’ cells will be processed and stored for potential manufacture of Tmod CAR T cell therapy upon relapse of their cancer.
Sites recruiting for BASECAMP-1 can be found here: Locations
Further information about this study can be found here: NCT04981119
EVEREST-1: A phase 1/2 study for solid tumors that express CEA
EVEREST-1 is a phase 1/2, multi-center, open-label study to evaluate the safety and efficacy of A2B530, an autologous logic-gated Tmod CAR T cell therapy.
EVEREST-1 is currently enrolling patients with non-small cell lung, colorectal, and pancreatic cancers.
Objective: Initially in Phase 1, evaluate the safety and tolerability of A2B530, and identify the maximum tolerated and recommended doses.
Study design: Phase 1/2, US-based, multicenter, open-label, non-randomized, dose-escalation study to evaluate adult patients with recurrent, unresectable, locally advanced, or metastatic non-small cell lung, colorectal, and pancreatic cancers. Participants will initially be enrolled in the BASECAMP-1 prescreening study and leukapheresed before entering EVEREST-1.
Sites recruiting for EVEREST-1 can be found here: Locations
Further information about this study can be found here: NCT05736731
EVEREST-2: A phase 1/2 study for solid tumors that express mesothelin (MSLN)
EVEREST-2 is a phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of A2B694, an autologous logic-gated Tmod CAR T cell therapy.
EVEREST-2 will enroll patients with mesothelioma; colorectal, non-small cell lung, pancreatic, or ovarian cancers, with recurrent unresectable or metastatic solid tumors that express the biomarker MSLN.
Objective: To evaluate the safety and tolerability of A2B694, and identify the maximum tolerated and recommended doses.
Study design: Phase 1/2, US-based, multicenter, open-label, non-randomized, dose-escalation study to evaluate germline heterozygous HLA-A*02 adults with recurrent, unresectable, locally advanced, or metastatic mesothelioma or colorectal, non-small cell lung, pancreatic, or ovarian cancers. Patients will initially be enrolled in the BASECAMP-1 pre-screening study and apheresed (have their blood removed to collect specific blood cells) before entering EVEREST-2.
Study centers recruiting for EVEREST-2 can be found here: Locations
Further information about this study can be found here: NCT06051695